US market entry of new biophotonic-based cervical scan tech delayed
This article was originally published in Clinica
Executive Summary
Guided Therapeutics' plans for the US launch of its LuViva noninvasive cervical cancer diagnostic device, a product that could potentially rival Pap smears and human papillomavirus (HPV) testing, have hit a snag after the company received a not-approvable letter from the FDA.